Study of IMC-003 for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with PAH (Group 1) through a specific heart test (right heart catheterization).
- Your PAH symptoms make you feel short of breath during daily activities (WHO class II or III).
- You can walk between 150 and 450 meters in 6 minutes (tested twice, a week apart).
- You have been on your current PAH medicines for at least 3 months without changes.
- You are not pregnant and agree to use effective birth control during the study and for 16 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This study tests an investigational drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It is open-label, meaning everyone knows they are getting the drug, and it is for people who have already been in a previous study of IKT-001.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Hear when a new Pulmonary Arterial Hypertension PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.